# Fluzoparib

Source: https://onco.cc/drugs/fluzoparib/  
OnCo record `fluzoparib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Fluzoparib is an oral parp inhibitor from Risen (Suzhou) Pharma Tech Co., Ltd., in registered phase 2 trials for metastatic cancer.

## Summary

Fluzoparib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Risen (Suzhou) Pharma Tech Co., Ltd., in metastatic cancer. A PARP inhibitor: the name stem -parib marks a small molecule that blocks the PARP DNA-repair enzyme, lethal to tumour cells that already lack a second repair pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral PARP inhibitor
- Mechanism: A PARP inhibitor: the name stem -parib marks a small molecule that blocks the PARP DNA-repair enzyme, lethal to tumour cells that already lack a second repair pathway.

## Sources

- ClinicalTrials.gov: trials of Fluzoparib: https://clinicaltrials.gov/search?intr=Fluzoparib

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Shanghai Junshi Biosciences](https://onco.cc/companies/junshi/)
- trials: [A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors](https://onco.cc/trials/nct06208410/)

---
JSON: https://onco.cc/api/v1/entities/fluzoparib.json